FDA Approves Daclatasvir for Hepatitis C Genotype 3, Technivie for Genotype 4

The U.S. Food and Drug Administration has approved 2 new treatments for hepatitis C virus (HCV) genotypes 3 and 4, which account for millions of cases worldwide. Daclatasvir (Daklinza) received the nod for use in combination with sofosbuvir (Sovaldi) for hard-to-treat genotype 3, while AbbVie received approval for its 2D paritaprevir/ritonavir/ombitasvir coformulation for genotype 4. Options remain limited, however, for people with liver cirrhosis.

Read more:

DDW 2015: Sofosbuvir/ Ledipasvir Cures Most Hepatitis C Patients with Cirrhosis

Sofosbuvir and ledipasvir -- the drugs in Harvoni -- are well-tolerated and highly effective for genotype 1 chronic hepatitis C patients with compensated cirrhosis, producing an overall cure rate of 96%, according to a pooled analysis of more than 500 participants in Phase 2 and 3 studies, according to a presentation at Digestive Disease Week 2015 this month in Washington, DC.

Read more:

Coverage of the 2015 International AIDS Society Conference

HIVandHepatitis.com coverage of the International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2015), July 19-22, in Vancouver, Canada.

Conference highlights include HIV treatment as prevention, pre-exposure prophylaxis (PrEP), new antiretroviral therapies, HIV cure research, hepatitis C and HIV/HCV coinfection, and global scale-up of prevention and treatment.

Full listing by topic

IAS 2015 website

7/22/15

DDW 2015: Sofosbuvir + Daclatasvir for 12 Weeks Cures Most HIV/HCV Coinfected Patients

Nearly all HIV/HCV coinfected patients treated for 12 weeks with an interferon- and ribavirin-free regimen of sofosbuvir (Sovaldi) and daclatasvir (Daklinza) achieved sustained virological response, but the cure rate fell to 76% for those treated for only 8 weeks, according to results from the ALLY-2 trial presented at Digestive Disease Week 2015 this month in Washington, DC.

Read more: